Novel Mass Spectrometry Method For The Quantification Of Immuno-suppressant Drug In Human Whole Blood | 5884
Journal of Analytical & Bioanalytical Techniques
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
The emergence of drug resistance variants has been the main stumbling blockade to the favorable clinical outcome of
chemotherapy. The resistance to one drug often results in cross-resistance to many, if not all, others in the same class.
Failure of the current HAART regimen due to drug resistance can severely limit second-line, third-line, and salvage treatment
options. The prime causes of drug resistance primarily include the inadequate exposure of the virus to antiretroviral agents,
poor adherence to complicated regimens and variability in drug pharmacokinetics. A number of mutations due to application of
almost all therapeutic antiHIV-1 drugs especially with nucleoside reverse transcriptase inhibitors (NRTI), non-nucleoside reverse
transcriptase inhibitors (NNRTI), anti-proteases and/or a combination of these regimens such as HAART have been selected into
different regions of pol gene of HIV-1 encoding the viral enzymes (HIV-1RT, protease and integrase). These mutations alter the
function of the target proteins of HIV-1, thus allowing the virus to replicate efficiently even in the presence of antiretroviral agents.
Very recently, it is known that these compounds also induce emergence of a compensatory mutation, which is found to be located
far from the active site of the enzyme protein. It repairs the functions of altered protein in a way that helps return them back
to near normal. It is presumed that these mutations influence the activity of the enzyme by inducing conformational flexibility;
however, the detailed mechanistic aspect of this event is still unclear. The present paper includes molecular mechanisms involved
in anti-HIV-1 drugs resistance, the development of new drugs that could be active against antiHIV-1 drugs resistant mutants,
new targets for effectively arresting the viral replication in human cells and other strategies to combat the scourge.
Bechan Sharma has completed his Ph.D. from Banaras Hindu University-Varanasi and Central Drug Research Institute-Lucknow, India in 1988. He
has been visiting scientist fo three years at University of Medicine and Dentistry of New Jersey-NJ Medical School, Newark, USA (2000-2002); and
as a Visiting Professor for two to four months at Italy, France, Thailand, Brazil, Germany and other countries. He is currently working as a senior
Professor and Ex-Chairman of Departments of Biochemistry and Biotechnology at the University of Allahabad, a premier Central University of India.
He has published more than 90 research papers in peer reviewed international journals of repute and one US patent to his credit. His Book on
`Recent Trends in Biotechnology` has been published in two volumes by Nova Publishers-NY, USA. He is on the reviewer panel of 65 International
/ National Journals and working as Chief-Editor/ Guest Editor/ Associate Editorial / Member Editorial Board of 26 International/ National journals. He
has produced 10 Ph.D. students in different areas of Biochemistry/Molecular Biology.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals